Organizer
Agilent Technologies
Agilent Technologies
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs.
Tags
LC/MS
LC/MS/MS
LC/TOF
LC/HRMS
LinkedIn Logo

Rapid Analysis of mRNA 5’ Capping and Poly-A Tailing with High-Resolution LC-MS

RECORD | Already taken place We, 30.11.2022
Topics: LC-MS is a robust, sensitive and specific technology for quality control of mRNA. Workflows for mRNA 5’ capping and poly-A tailing. Detection and characterization of product-related impurities.
Go to the webinar
Agilent Technologies: Rapid Analysis of mRNA 5’ Capping and Poly-A Tailing with High-Resolution LC-MS
Agilent Technologies: Rapid Analysis of mRNA 5’ Capping and Poly-A Tailing with High-Resolution LC-MS

Industrial-scale production of mRNA has taken on renewed importance due to the on-going pandemic. Efficient translation of mRNA to protein depends critically on: (i) 5’-terminal capping, and (ii) 3’ terminal polyadenylation, which can be considered critical quality attributes that must be characterized and monitored.

This presentation will show that:
  • mRNA capping can be analyzed by LC-MS within 75 minutes by taking advantage of a thermostable enzyme to rapidly liberate 5’ terminal oligonucleotides.
  • Certain enzymes commonly used during in vitro transcription can incorporate non-templated nucleotides into both 5’ and 3’ terminal regions.
  • Non-templated nucleotides can be considered product-related impurities and can be detected and quantified by LC-MS.
Three learning objectives:
  • LC-MS is a robust, sensitive and specific technology for quality control of mRNA.
  • Workflows for analysis of mRNA 5’ capping and poly-A tailing
  • Detection and characterization of product-related impurities stemming from incorporation of non-templated nucleotides

Presenter: Brian Liau, PhD (Solution Development Scientist, Singapore, Agilent Technologies, Inc.)

Brian Liau obtained his bachelor’s degree at Johns Hopkins University and his PhD at Duke University. Currently based at Agilent’s Global Solution Development Center in Singapore, he develops new LC-MS and spectroscopic techniques to ensure the quality and safety of next-generation therapies such as AAV vectors and mRNA vaccines. Prior to joining Agilent, he was a research fellow at the Bioprocessing Technology Institute (A*STAR).

Agilent Technologies
LinkedIn Logo
 

Related content

Comprehensive and Robust Analysis of Ultrashort- to Long-Chain PFAS, PAE, OPE, and PAH

Applications
| 2026 | Agilent Technologies
Instrumentation
LC/MS, LC/MS/MS, LC/TOF, LC/HRMS
Manufacturer
Agilent Technologies, Plasmion
Industries
Environmental

UPLC™ Separation of Fifteen Bisphenols Using a Waters Acquity™ Biphenyl RP Column with MaxPeak™ Premier Technology and UV Detection

Applications
| 2026 | Waters
Instrumentation
Consumables, LC columns, HPLC
Manufacturer
Waters
Industries
Pharma & Biopharma

Achieving Low‑ppb Bisphenol Quantitation with the Agilent InfinityLab Pro iQ Mass Detector

Applications
| 2026 | Agilent Technologies
Instrumentation
LC/MS, LC/SQ
Manufacturer
Agilent Technologies
Industries
Materials Testing

ECL detection of fentanyl

Applications
| 2026 | Metrohm
Instrumentation
Electrochemistry
Manufacturer
Metrohm
Industries
Forensics

Early-stage drug metabolite quantitation without radiolabels

Applications
| 2026 | Thermo Fisher Scientific
Instrumentation
HPLC, LC/MS, LC/SQ
Manufacturer
Thermo Fisher Scientific
Industries
Pharma & Biopharma, Metabolomics
Other projects
GCMS
ICPMS
Follow us
FacebookX (Twitter)LinkedInYouTube
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike